<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/83D87776-5958-42AE-889D-B8AECF16B468"><gtr:id>83D87776-5958-42AE-889D-B8AECF16B468</gtr:id><gtr:name>University of Leeds</gtr:name><gtr:department>Leeds Institute of Molecular Medicine</gtr:department><gtr:address><gtr:line1>University of Leeds</gtr:line1><gtr:line4>Leeds</gtr:line4><gtr:line5>West Yorkshire</gtr:line5><gtr:postCode>LS2 9JT</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/83D87776-5958-42AE-889D-B8AECF16B468"><gtr:id>83D87776-5958-42AE-889D-B8AECF16B468</gtr:id><gtr:name>University of Leeds</gtr:name><gtr:address><gtr:line1>University of Leeds</gtr:line1><gtr:line4>Leeds</gtr:line4><gtr:line5>West Yorkshire</gtr:line5><gtr:postCode>LS2 9JT</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/60C77415-2DC0-4359-920E-6BEAA3C15CAB"><gtr:id>60C77415-2DC0-4359-920E-6BEAA3C15CAB</gtr:id><gtr:firstName>Terence</gtr:firstName><gtr:surname>Rabbitts</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0600914"><gtr:id>1075D976-CA90-4D73-9D30-E8B222B6C679</gtr:id><gtr:title>The role of chromosomal abnormalities in cancer and experimental therapeutics</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0600914</gtr:grantReference><gtr:abstractText>Cancer affects around a third of all adults during their life and as life expectancy increases, cancer incidence will increase in the following decades. The occurrence of mutations in cancer is indicative of specific changes that drive tumour development and which can be targets for new therapies that would not have the side effects as conventional treatments. One the most obvious changes seen in cancer cells is chromosomal translocation, which result from joining between two different chromosomes during cell division. These translocations usually have an effect on a gene or even fuse two genes together giving tumour-specific markers and new therapeutic targets. The problem is that these molecules are inside the cell and are not usually enzymes which can relatively easily be inactivated by drugs that are able to enter the cancer cells. We need new types of drugs to inactivate the chromosomal translocation-proteins and new ways of modelling chromosomal translocations to test out the novel drugs in an in vivo preclinical setting. The aim of the work proposed in the application is to develop new methods in both areas. We will develop ways to rapidly produce bespoke reagents that can interfere with chromosomal translocation-proteins to block cancer growth or, in some settings, to kill tumour cells whilst sparing normal counterparts. We will also develop methods to create in vivo models of human chromosomal translocations that can be used to assess the biological basis of cancer and as a setting for developing new therapeutic strategies. The aim is to evaluate the possible use of novel reagents for cancer patients in these models, either as single therapeutic entities or in combination with existing treatment modalities. Our long term aim is to treat patients with regimes shown to be effective in vivo.</gtr:abstractText><gtr:technicalSummary>The study of chromosomal translocations is important to understand cancer initiation and progression as well as providing new therapeutic targets and molecules that can be evaluated in the preclinical setting of mouse cancer models. Cancer arises by somatic genetic changes that include gross chromosomal abnormalities. Chromosomal translocations are particularly prevalent in haematopoietic and mesenchymal neoplasias and pinpoint an exact location in the genome where a change has occurred, at which an altered gene or gene fusion is found. Therefore defining and studying the breakpoint provides the means to quickly identify the genetic basis of the tumour formation that follows a chromosomal rearrangement. This is a powerful system in cancer biology to define the biological steps from the cancer stem cell to the overt tumour and its metastatic invasive stage. We will develop faster and more complex mouse models to mimic human cancer employing homologous recombination in ES cells and generation of mice from these. As an example, we will model the MLL-AF4 fusion to develop a system to study the leukaemia and analyse new drugs for this fusion-associated leukaemia which has a high incidence in childhood acute lymphoblastic leukaemia and is a poor prognostic indicator. The mouse models will form prototypes for testing macromolecular drugs (macrodrugs) and delivery systems for these. We will generate new molecules for interference with the function of oncogenic proteins in human cancer, including leukaemias, sarcomas and carcinomas. We have previously shown that single immunoglobulin variable region domains can be used as powerful functional entities inside cells to interact with targets and cause phenotypic knock-out. These intrabodies will be developed against key cancer targets such as MLL-AF4 in leukaemia or EWS-ERG or FLI1 in sarcoma. We will expand our range of techniques in the intrabody area to facilitate isolation of molecules that bind to defined parts of targets, such as the junctional region of fusion proteins. These molecules will be tested using in vivo models as a preclinical setting since novel therapies must be evaluated in the context of a model system prior to use in patients. In the medium term, we predict that we can use the reagents ex vivo with human cancers and ultimately in vivo either as macromolecular drugs in their own right or following development of mimetics.</gtr:technicalSummary><gtr:fund><gtr:end>2012-04-17</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2007-04-18</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>1888733</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>The present invention relates to methods of isolating synergistic single domains and constitution of functional antibody components or antibodies and especially, but not exclusively, production of antibodies to naturally folded proteins. The methods include selecting pairs of single domains for coordinate binding to the same epitopic region of a target site on an antigen, the invention also includes methods of screening single domain libraries or the like for synergistic single domains, methods of producing antibodies and inter alia products for use therewith.</gtr:description><gtr:grantRef>G0600914</gtr:grantRef><gtr:id>7B94B4E9-1191-4449-BE5B-99918FECB0B2</gtr:id><gtr:impact>None as yet</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>981AC02F84C</gtr:outcomeId><gtr:patentId>US2010143939</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Antibody Production</gtr:title><gtr:yearProtectionGranted>2010</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>The present invention relates to a screening method for identifying small-molecule candidate therapeutics capable of inhibiting or interfering with intracellular protein-protein interactions, especially cancer associated oncogenic protein interactions. The present invention also provides methods and assays for, inter alia, rationalized drug design based on identifying small molecular weight protein-protein interaction inhibitor molecules that emulate antibody therapeutic products and uses thereof.</gtr:description><gtr:grantRef>G0600914</gtr:grantRef><gtr:id>C5C5078D-1CE8-4B4C-ADFC-DB6259214084</gtr:id><gtr:impact>None</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>545a127e70ab36.54177775</gtr:outcomeId><gtr:protection>Patent application published</gtr:protection><gtr:title>Identification of Candidate Therapeutics</gtr:title><gtr:yearProtectionGranted>2011</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>A general immunoglobulin-target assay system is provided, in which a positive outcome (the generation of a signal) depends only on the intracellular interaction of immunoglobulin with target. This can be accomplished for many immunoglobulins expressed in yeast and/or in mammalian cells and allows the selection of immunoglobulins which are capable of functioning in an intracellular environment.</gtr:description><gtr:grantRef>G0600914</gtr:grantRef><gtr:id>B258011B-EDB0-486E-892E-93CAE114E227</gtr:id><gtr:impact>Invention relates to discovery of antibodies that function in cells. Methods for selection of intracellular antibodies specific for antigens in the cell are described. Patent filed. Now abandoned.</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>A93A5EE48FC</gtr:outcomeId><gtr:patentId>US7569390</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Intracellular Selection</gtr:title><gtr:yearProtectionGranted>2009</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>chimaeric mice developing chromosomal translocations and aml</gtr:description><gtr:id>AAEAC3C9-A862-41EC-B6E1-E5FC96114DAF</gtr:id><gtr:impact>none yet</gtr:impact><gtr:outcomeId>222A1662A7F</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>mouse model of aml</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>DEE611F0-ADBB-4112-9B9A-B26D439E333F</gtr:id><gtr:title>Protocol for the selection of single-domain antibody fragments by third generation intracellular antibody capture.</gtr:title><gtr:parentPublicationTitle>Nature protocols</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9280b9f441ca1d50b85d73905fa208a8"><gtr:id>9280b9f441ca1d50b85d73905fa208a8</gtr:id><gtr:otherNames>Tanaka T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1750-2799</gtr:issn><gtr:outcomeId>A250EFDBEE2</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EA350BC8-26E7-410A-AB14-53B3EE445AF2</gtr:id><gtr:title>Selection of complementary single-variable domains for building monoclonal antibodies to native proteins.</gtr:title><gtr:parentPublicationTitle>Nucleic acids research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9280b9f441ca1d50b85d73905fa208a8"><gtr:id>9280b9f441ca1d50b85d73905fa208a8</gtr:id><gtr:otherNames>Tanaka T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0305-1048</gtr:issn><gtr:outcomeId>3323AC98013</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>07358DD7-29CE-40E1-BBCD-20E096313006</gtr:id><gtr:title>Distinct pathways regulated by menin and by MLL1 in hematopoietic stem cells and developing B cells.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/93e0024b1d7ccf0ae91dcd4ac4bce74d"><gtr:id>93e0024b1d7ccf0ae91dcd4ac4bce74d</gtr:id><gtr:otherNames>Li BE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>pm_15100_20_23908472</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6D9243B3-B80B-4E27-AEEF-9E78B72F7B2C</gtr:id><gtr:title>MLL gene fusions in human leukaemias: in vivo modelling to recapitulate these primary tumourigenic events.</gtr:title><gtr:parentPublicationTitle>International journal of hematology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1058a716f43239e0a6553399ba518967"><gtr:id>1058a716f43239e0a6553399ba518967</gtr:id><gtr:otherNames>Rodriguez-Perales S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0925-5710</gtr:issn><gtr:outcomeId>E46195A636F</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C7588CA4-C93F-4714-A003-52EC76549FBF</gtr:id><gtr:title>The Lmo2 oncogene initiates leukemia in mice by inducing thymocyte self-renewal.</gtr:title><gtr:parentPublicationTitle>Science (New York, N.Y.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c6db4980da9950901817c6329d35d045"><gtr:id>c6db4980da9950901817c6329d35d045</gtr:id><gtr:otherNames>McCormack MP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0036-8075</gtr:issn><gtr:outcomeId>Wn3UzxfcyNb</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>779E54B2-9894-4415-BEBD-CFC60C472C7F</gtr:id><gtr:title>Preclinical modeling of cytosine arabinoside response in Mll-Enl translocator mouse leukemias.</gtr:title><gtr:parentPublicationTitle>Molecular cancer therapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fbcad82585b37e480939c9b187de13c5"><gtr:id>fbcad82585b37e480939c9b187de13c5</gtr:id><gtr:otherNames>Cano F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1535-7163</gtr:issn><gtr:outcomeId>D321998B7DF</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>ED147AF6-48C2-4A32-A2AF-00A478B02D98</gtr:id><gtr:title>Selection of human single domain antibodies recognizing the CMYC protein using enhanced intracellular antibody capture.</gtr:title><gtr:parentPublicationTitle>Journal of immunological methods</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9c5dd22e69937cc91b3f56ac7eae76ea"><gtr:id>9c5dd22e69937cc91b3f56ac7eae76ea</gtr:id><gtr:otherNames>Zeng J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0022-1759</gtr:issn><gtr:outcomeId>56d80ea454d3b7.60224734</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D2B3ECE3-B750-4D77-A207-58289FBFE750</gtr:id><gtr:title>Nonreciprocal chromosomal translocations in renal cancer involve multiple DSBs and NHEJ associated with breakpoint inversion but not necessarily with transcription.</gtr:title><gtr:parentPublicationTitle>Genes, chromosomes &amp; cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ec7718605084ef32a3392fb3199ce1a0"><gtr:id>ec7718605084ef32a3392fb3199ce1a0</gtr:id><gtr:otherNames>Ali H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1045-2257</gtr:issn><gtr:outcomeId>pm_15100_20_23341332</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AF0F9C1A-28B7-4DD9-9FC6-41E660ACD925</gtr:id><gtr:title>Intracellular antibody capture (IAC) methods for single domain antibodies.</gtr:title><gtr:parentPublicationTitle>Methods in molecular biology (Clifton, N.J.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9280b9f441ca1d50b85d73905fa208a8"><gtr:id>9280b9f441ca1d50b85d73905fa208a8</gtr:id><gtr:otherNames>Tanaka T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1064-3745</gtr:issn><gtr:outcomeId>pm_15100_20_22886251</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>ED848254-FADB-45CF-B843-0A6E4A056D19</gtr:id><gtr:title>Progressive 3q amplification consistently targets SOX2 in preinvasive squamous lung cancer.</gtr:title><gtr:parentPublicationTitle>American journal of respiratory and critical care medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/571a0cb275300a32e9185f4502768350"><gtr:id>571a0cb275300a32e9185f4502768350</gtr:id><gtr:otherNames>McCaughan F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1073-449X</gtr:issn><gtr:outcomeId>pm_15100_20_20299530</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8A20D8C5-A0F3-428B-9537-4A1DBEEF8487</gtr:id><gtr:title>Microdissection molecular copy-number counting (microMCC)--unlocking cancer archives with digital PCR.</gtr:title><gtr:parentPublicationTitle>The Journal of pathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/571a0cb275300a32e9185f4502768350"><gtr:id>571a0cb275300a32e9185f4502768350</gtr:id><gtr:otherNames>McCaughan F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0022-3417</gtr:issn><gtr:outcomeId>941D8B44C77</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DA54CDE7-0601-4233-8042-F4E5CE3BC2F3</gtr:id><gtr:title>A conditional model of MLL-AF4 B-cell tumourigenesis using invertor technology.</gtr:title><gtr:parentPublicationTitle>Oncogene</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4e274af2a442e367593b86533ee97c3b"><gtr:id>4e274af2a442e367593b86533ee97c3b</gtr:id><gtr:otherNames>Metzler M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0950-9232</gtr:issn><gtr:outcomeId>355900946AB</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>657F31AB-FE90-4EED-9E39-DE1C6D66F6F8</gtr:id><gtr:title>Selection of functional single domain antibody fragments for interfering with protein-protein interactions inside cells: a &amp;quot;one plasmid&amp;quot; mammalian two-hybrid system.</gtr:title><gtr:parentPublicationTitle>Methods in molecular biology (Clifton, N.J.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9280b9f441ca1d50b85d73905fa208a8"><gtr:id>9280b9f441ca1d50b85d73905fa208a8</gtr:id><gtr:otherNames>Tanaka T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1064-3745</gtr:issn><gtr:outcomeId>pm_15100_20_22886252</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2C9E3CED-E63E-4395-89D0-8930C5E771D0</gtr:id><gtr:title>Single domain intracellular antibodies from diverse libraries: emphasizing dual functions of LMO2 protein interactions using a single VH domain.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9280b9f441ca1d50b85d73905fa208a8"><gtr:id>9280b9f441ca1d50b85d73905fa208a8</gtr:id><gtr:otherNames>Tanaka T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>pm_15100_20_20980262</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E44CBEBD-FF76-4348-B482-3025C6981F7E</gtr:id><gtr:title>Intracellular antibodies and cancer: new technologies offer therapeutic opportunities.</gtr:title><gtr:parentPublicationTitle>BioEssays : news and reviews in molecular, cellular and developmental biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/eec44606501853a698c913b0b0281b4d"><gtr:id>eec44606501853a698c913b0b0281b4d</gtr:id><gtr:otherNames>P?rez-Mart?nez D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0265-9247</gtr:issn><gtr:outcomeId>pm_15100_20_20544739</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3C854BD6-3906-4806-AA5E-A92885FF4484</gtr:id><gtr:title>Commonality but diversity in cancer gene fusions.</gtr:title><gtr:parentPublicationTitle>Cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e51d5da25fa6ee3beb07f46b5f732106"><gtr:id>e51d5da25fa6ee3beb07f46b5f732106</gtr:id><gtr:otherNames>Rabbitts TH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0092-8674</gtr:issn><gtr:outcomeId>9BBC30DF757</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4FF8A91D-B7C4-428F-816C-DDE6D86FFDAD</gtr:id><gtr:title>Interfering with RAS-effector protein interactions prevent RAS-dependent tumour initiation and causes stop-start control of cancer growth.</gtr:title><gtr:parentPublicationTitle>Oncogene</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9280b9f441ca1d50b85d73905fa208a8"><gtr:id>9280b9f441ca1d50b85d73905fa208a8</gtr:id><gtr:otherNames>Tanaka T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0950-9232</gtr:issn><gtr:outcomeId>QFQADwL2W5M</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7516C4A5-9728-4A57-858B-BECDB51B3F74</gtr:id><gtr:title>Leukaemia lineage specification caused by cell-specific Mll-Enl translocations.</gtr:title><gtr:parentPublicationTitle>Oncogene</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fbcad82585b37e480939c9b187de13c5"><gtr:id>fbcad82585b37e480939c9b187de13c5</gtr:id><gtr:otherNames>Cano F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0950-9232</gtr:issn><gtr:outcomeId>7ACF80626BA</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F9135189-6392-4553-869B-BABAA519B213</gtr:id><gtr:title>LMO2 at 25 years: a paradigm of chromosomal translocation proteins.</gtr:title><gtr:parentPublicationTitle>Open biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/590bf6865bfab157d61e6d2761727937"><gtr:id>590bf6865bfab157d61e6d2761727937</gtr:id><gtr:otherNames>Chambers J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2046-2441</gtr:issn><gtr:outcomeId>56e00c9ced4ca3.25218630</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6E7006F9-518D-47C0-BD67-B2836DFCD2D9</gtr:id><gtr:title>Targeting LMO2 with a peptide aptamer establishes a necessary function in overt T-cell neoplasia.</gtr:title><gtr:parentPublicationTitle>Cancer research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1dac72a0ae4dc9317788012bda34c3cc"><gtr:id>1dac72a0ae4dc9317788012bda34c3cc</gtr:id><gtr:otherNames>Appert A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0008-5472</gtr:issn><gtr:outcomeId>2EAB61B9628</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BBE5C0FE-3257-4742-B208-359708E3A0B3</gtr:id><gtr:title>Modeling chromosomal translocations using conditional alleles to recapitulate initiating events in human leukemias.</gtr:title><gtr:parentPublicationTitle>Journal of the National Cancer Institute. Monographs</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b299705a31f260577325faad20fbe3e3"><gtr:id>b299705a31f260577325faad20fbe3e3</gtr:id><gtr:otherNames>Lobato MN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1052-6773</gtr:issn><gtr:outcomeId>F28C9D94AF9</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1302910C-778A-42B3-85AB-643E3BA8AD53</gtr:id><gtr:title>Exploring the surfaceome of Ewing sarcoma identifies a new and unique therapeutic target.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e4005dccb25e6d372cda6ab7db0fe727"><gtr:id>e4005dccb25e6d372cda6ab7db0fe727</gtr:id><gtr:otherNames>Town J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>585d51d001c253.06103900</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>22D5FEEF-42DB-4130-8F29-6E298524C47B</gtr:id><gtr:title>An antibody inhibitor of the LMO2-protein complex blocks its normal and tumorigenic functions.</gtr:title><gtr:parentPublicationTitle>Oncogene</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5dd90bb0d9d71685286339c9d2846a35"><gtr:id>5dd90bb0d9d71685286339c9d2846a35</gtr:id><gtr:otherNames>Nam CH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0950-9232</gtr:issn><gtr:outcomeId>5DF5C8D48DF</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B7E1ABBA-7675-4B2B-A50B-53644B81B7E4</gtr:id><gtr:title>The role of LMO2 in development and in T cell leukemia after chromosomal translocation or retroviral insertion.</gtr:title><gtr:parentPublicationTitle>Molecular therapy : the journal of the American Society of Gene Therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5dd90bb0d9d71685286339c9d2846a35"><gtr:id>5dd90bb0d9d71685286339c9d2846a35</gtr:id><gtr:otherNames>Nam CH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1525-0016</gtr:issn><gtr:outcomeId>35E04EC3255</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5649C378-04F7-4733-8E8C-BFF42F522515</gtr:id><gtr:title>PCRPi: Presaging Critical Residues in Protein interfaces, a new computational tool to chart hot spots in protein interfaces.</gtr:title><gtr:parentPublicationTitle>Nucleic acids research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c7329d5d082e50ac2a9eaf96183237a8"><gtr:id>c7329d5d082e50ac2a9eaf96183237a8</gtr:id><gtr:otherNames>Assi SA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0305-1048</gtr:issn><gtr:outcomeId>07B3C7DCFBC</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0600914</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>